Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Status:
Recruiting
Trial end date:
2032-09-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, international, randomized phase III trial to compare the
efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL
patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously
treated with at least one prior systemic treatment and not more than three prior lines are
eligible. Previous treatment line must include at least one systemic line with a drug
targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP,
R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as
Ibrutinib.
The patients will be Randomized as follows:
Arm A - Experimental arm:
• Mosunetuzumab-Lenalidomide
Arm B - Comparator arms ( Investigator Choices):
- Rituximab-Lenalidomide
- Rituximab-Bendamustine
- Rituximab-CHOP